Figure 4.

Effects of FX knockdown on circulating levels of FX zymogen and the ex vivo clotting assays. Serial blood sampling at day 0 (baseline), and day 2, 4, and 7 postdosing were performed in the in vivo study described in Figure 3. Circulating levels of FX zymogen (as determined by the FXa enzyme assay) (a), ex vivo prothrombin time (PT) (b), and ex vivo activated partial thromboplastin time (aPTT) (c) in the various treatment groups at all time points were examined. All results are expressed as mean and standard error of mean. *P < 0.05, **P < 0.01, ***P < 0.001 compared to nt control of the respective time point. Percent change from the nt control where there is a statistical significance is noted on the graph.